This document provides compounds, compositions, and methods for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, compounds, compositions, and methods for using one or more inhibitors of SCD1 to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)), thyroid cancer, or liver cancer; or to increase the efficacy of treatment for the same.

The invention relates to new benzonitrile derivatives of the formula (I) wherein R.sup.1 to R.sup.3 and A are as defined in the description and Claims, to their medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them. ##STR00001##

The invention relates to new benzonitrile derivatives of the formula (I) wherein R.sup.1 to R.sup.3 and A are as defined in the description and Claims, to their medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them. ##STR00001##

The invention relates to new benzonitrile derivatives of the formula (I) wherein R.sup.1 to R.sup.3 and A are as defined in the description and Claims, to their medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

##STR00001##

The present invention relates to a medicament for treating or preventing a disease related to orexin receptor, especially orexin receptor type 2, comprising a new compound having a urea structure or a pharmaceutically acceptable salt thereof as an active ingredient. In more detail, the present invention relates to a medicament for treating or preventing a disease such as narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome.

The present invention relates to inhibitors of 11- hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11- hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.

The present invention relates to inhibitors of 11- hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11- hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.

The present invention relates to inhibitors of 11- hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11- hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.

The present invention relates to inhibitors of 11- hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11- hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.

The present invention relates to inhibitors of 11- hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11- hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.